Sorivudine
Based on 1 Customer Validation
Sorivudine (BV-araU) is an orally active synthetic pyrimidine nucleoside antimetabolite agent. Sorivudine derives its antiviral activity from selective conversion by a specific thymidine kinase present in certain DNA viruses to nucleotides, which can in turn interfere with viral DNA synthesis.
For research use only. We do not sell to patients.
- Purity: 99.69%
- CAS No.: 77181-69-2
- Formula: C11H13BrN2O6
- Molecular Weight:349.13
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Glycoside Compound Library
HY-L042
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
Heterocyclic Compound Library
HY-L138
-
Withdrawn Drug Compound Library
HY-L140
-
Off-patent Drug Library
HY-L141
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-HSB-2 | IC50 |
>100 μg/mL
Compound: BAVU
|
Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
|
[PMID: 9216836] |
| HEL | ED50 |
>50 μg/mL
Compound: BAVU
|
Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.
Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.
|
[PMID: 9216836] |
| HEL | ED50 |
0.0013 μg/mL
Compound: BAVU
|
Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.
Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.
|
[PMID: 9216836] |
| HEL | ED50 |
0.036 μg/mL
Compound: BAVU
|
Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.
Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.
|
[PMID: 9216836] |
| HEL | ED50 |
62 μg/mL
Compound: BAVU
|
Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.
Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.
|
[PMID: 9216836] |
| OST | IC50 |
>=250 μM
Compound: sorivudine
|
Inhibition of proliferation of thymidine kinase deficient OST cells
Inhibition of proliferation of thymidine kinase deficient OST cells
|
[PMID: 17518459] |
Sorivudine (BV-araU) inhibits strains of HSV-1 and HSV-2 (wild-type strains VR-3 and UW-268) with ID50s (50% inhibitory dose) of 0.39 and 0.67 μM, respectively[1].
Sorivudine has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus[1].
Sorivudine (BV-araU) is a pyrimidine nucleoside analog which has in vitro inhibitory activity against varicella zoster virus (VZV) at concentrations of 00001-0.004 mg/ml These concentrations are over 1000-fold lower than those which are required for the inhibition of VZV replication by acyclovir 3 Sorivudine also inhibits HSV-I replication at concentrations ranging from 0.03-0.1 mg/ml[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 77181-69-2
-
Appearance Solid
-
Molecular Weight 349.13
-
Formula C11H13BrN2O6
-
Color White to off-white
-
SMILES
O=C1NC(C(/C=C/Br)=CN1[C@H]2[C@H]([C@@H]([C@@H](CO)O2)O)O)=O
-
Synonyms
BV-araU
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 125 mg/mL (358.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.96 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.96 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Diasio RB, et al. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol. 1998 Jul;46(1):1-4. [Content Brief]
[2]. Whitley RJ, et al. Sorivudine: a potent inhibitor of varicella zoster virus replication.Adv Exp Med Biol. 1996;394:41-4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8643 mL | 14.3213 mL | 28.6426 mL | 71.6066 mL |
| 5 mM | 0.5729 mL | 2.8643 mL | 5.7285 mL | 14.3213 mL | |
| 10 mM | 0.2864 mL | 1.4321 mL | 2.8643 mL | 7.1607 mL | |
| 15 mM | 0.1910 mL | 0.9548 mL | 1.9095 mL | 4.7738 mL | |
| 20 mM | 0.1432 mL | 0.7161 mL | 1.4321 mL | 3.5803 mL | |
| 25 mM | 0.1146 mL | 0.5729 mL | 1.1457 mL | 2.8643 mL | |
| 30 mM | 0.0955 mL | 0.4774 mL | 0.9548 mL | 2.3869 mL | |
| 40 mM | 0.0716 mL | 0.3580 mL | 0.7161 mL | 1.7902 mL | |
| 50 mM | 0.0573 mL | 0.2864 mL | 0.5729 mL | 1.4321 mL | |
| 60 mM | 0.0477 mL | 0.2387 mL | 0.4774 mL | 1.1934 mL | |
| 80 mM | 0.0358 mL | 0.1790 mL | 0.3580 mL | 0.8951 mL | |
| 100 mM | 0.0286 mL | 0.1432 mL | 0.2864 mL | 0.7161 mL |
Sorivudine Related Classifications
HY-123032 Related Classifications
Powered by Bioz